(original) (raw)

TY - JOUR AU - Cherney, David Z. I. AU - Charbonnel, Bernard AU - Cosentino, Francesco AU - Dagogo-Jack, Samuel AU - McGuire, Darren K. AU - Pratley, Richard AU - Shih, Weichung J. AU - Frederich, Robert AU - Maldonado, Mario AU - Pong, Annpey AU - Cannon, Christopher P. AU - on behalf of the VERTIS CV Investigators PY - 2021 DA - 2021/06/01 TI - Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial JO - Diabetologia SP - 1256 EP - 1267 VL - 64 IS - 6 AB - In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death) with ertugliflozin compared with placebo as 0.81 (0.63, 1.04). The effect of ertugliflozin on exploratory kidney-related outcomes was evaluated using data from the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881). SN - 1432-0428 UR - https://doi.org/10.1007/s00125-021-05407-5 DO - 10.1007/s00125-021-05407-5 ID - Cherney2021 ER -